Evidence map›Paper›PMID 36445642›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Recommendations of the Spanish brachytherapy group of the Spanish Society of Radiation Oncology and the Spanish Society of Medical Physics for interstitial high-dose-rate brachytherapy for gynaecologic malignancies.

Cristina Gutiérrez Miguélez, Silvia Rodríguez Villalba, Elena Villafranca Iturre, Naiara Fuentemilla Urio, Jose Richart Sancho, Sofía Córdoba Lago, Francisco Pino Sorroche, Ruth Gracia Lucio, Antonio Herreros Martínez, Dina Najjari-Jamal and 1 more

Erratum issuedOpen access · hybridFull text readReview
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Cristina Gutiérrez Miguélez *Radiation Oncology Department, Institut Català d'Oncologia, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB) Catalonia, Hospitalet de Llobregat, Spain. cgutierrezm@iconcologia.net.ORCID http://orcid.org/0000-0002-6944-772X
Silvia Rodríguez Villalba *Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Spain.
Elena Villafranca IturreRadiation Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Naiara Fuentemilla UrioRadiation Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Jose Richart SanchoRadiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Spain.
Sofía Córdoba LagoRadiation Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Francisco Pino SorrocheRadiophysics Department, Institut Català d'Oncologia, Hospitalet de Llobregat, Catalonia, Spain.
Ruth Gracia LucioRadiophysics Department, Institut Català d'Oncologia, Hospitalet de Llobregat, Catalonia, Spain.
Antonio Herreros MartínezRadiophysics Department, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
Dina Najjari-JamalRadiation Oncology Department, Institut Català d'Oncologia, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB) Catalonia, Hospitalet de Llobregat, Spain.
GEB (Spanish Brachytherapy Group)
Institut Català d'Oncologia · ESComplejo Hospitalario de Navarra · ESHospital Clínica Benidorm · ESHospital Clínic de Barcelona · ESHospital Universitario Puerta de Hierro Majadahonda · ESHospital Universitari Sant Joan D'Alacant · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present document includes consensus-based recommendations from the Brachytherapy Group (GEB) of the Spanish Society of Radiation Oncology (SEOR) and the Spanish Society of Medical Physics (SEFM) for interstitial high-dose-rate (HDR) brachytherapy (BT) for gynaecologic malignancies. A nine-item survey-which included questions on experience with interstitial BT; indications and technique; applicator type; magnetic resonance imaging (MRI)-based planning; dose; fractionation schedule; and treatment planning-was sent to all radiation oncology departments (n = 174) in Spain in 2021. Responses were received from 36 centres (50% of all centres [n = 72] with a BT unit). The consensus-based recommendations presented here are based on a review of the available literature, professional experience among the group of experts, and in-person discussions held during the annual meeting of these two societies. We describe the results of the survey and the following: indications; contraindications; patient selection; description of applicators; role of imaging in planning; contouring; dose prescription; dosimetric reconstruction; optimisation; and dose indications for cancers of the cervix, vagina, and vulva. The various clinical scenarios in which interstitial BT is used in the treatment of gynaecological tumours are described in detail, including cervix intracavitary/interstitial hybrid HDR-BT; cervix perineal templates/freehand implants; primary vaginal malignancies/vaginal recurrences; and vulvar interstitial implants.

Indexed as

BrachytherapyGenital Neoplasms, FemaleRadiation OncologyUterine Cervical NeoplasmsVaginal NeoplasmsFemaleHumansPhysicsRadiotherapy DosageRadiotherapy Planning, Computer-AssistedConsensusInterstitial high-dose-rate gynaecological brachytherapyRecommendationsTechnical, dosimetric aspects

Identifiers

PMID36445642
PMCPMC10025210
OpenAlexW4310464000

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read50
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.